24. (new) The pharmaceutical composition of claim 23 wherein the liposomes have an average diameter of about 100 nm to about 150 nm.

25. (new) The pharmaceutical composition of claim 23 wherein the liposomes have an average diameter of about 114 ± 7 nm.

26. (new) The pharmaceutical composition of claim 23 further comprising a pharmaceutically acceptable carrier.

27. (new) The pharmaceutical composition of claim 26 wherein the pharmaceutically acceptable carrier is selected from the group consisting of sterilized water, sterilized buffered water, sterilized saline solution, and a sterilized aqueous solution containing a compound selected from the group consisting of glycine, glycoproteins, albumin, lipoprotein, globulin, pH adjusting agents, buffering agents, tonicity adjusting agents, sodium acetate, sodium lactate, potassium chloride, calcium chloride, sodium chloride, and mixtures thereof.

28. (new) The pharmaceutical composition of claim 26 wherein the composition is lyophilized.

29. (new) The pharmaceutical composition of claim 26 wherein the concentration of liposomes in the carrier is about 200 mg/ml.

30. (new) The pharmaceutical composition of claim 26 wherein the concentration of liposomes in the carrier is about 100 mg/ml.

31. (new) The pharmaceutical composition of claim 26 wherein the concentration of liposomes in the carrier is in the range of 20-200 mg/ml.

32. (new) The pharmaceutical composition of claim 26 wherein the concentration of liposomes in the carrier is in the range of 50-150 mg/ml.

33. (new) The pharmaceutical composition of claim 23 wherein the liposomes are bound to apoproteins, lecithin-cholesterol acyltransferase, albumin or mixtures thereof.

34. (new) The pharmaceutical composition of claim 23, wherein the phospholipid is selected from the group consisting of egg phosphatidylcholine, egg phosphatidylglycerol, distearoylphosphatidylcholine, distearoylphosphatidylglycerol, phosphatidylcholine, phosphatidylglycerol, lecithin, β,γ-dipalmitoyl-α-lecithin, sphingomyelin, phosphatidylserine, phosphatidic acid, N-(2,3-di (9-(Z)-octadecenyloxy))-prop-1-yl-N,N,N-trimethylammonium chloride, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylinositol, cephalin, cardiolipin, cerebrosides, dicetylphosphate, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylglycerol, dioleoylphosphatidylglycerol, palmitoyl-oleoyl-phosphatidylcholine, di-stearoyl-phosphatidylcholine, stearoyl-palmitoyl-phosphatidylcholine, di-palmitoyl-phosphatidylethanolamine, di-stearoyl-phosphatidylethanolamine, di-myrstoyl-phosphatidylserine, di-oleyl-phosphatidylcholine, and mixtures thereof.

A1

35. (new) The pharmaceutical composition of claim 23, wherein the phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, and mixtures thereof.

36. (new) The pharmaceutical composition of claim 23, wherein the liposomes are obtainable by extruding phospholipid through filters having a pore diameter of 0.1 micron.

37. (new) The pharmaceutical composition of claim 23, wherein the liposomes are obtainable by extruding phospholipid through polycarbonate filters.

38. (new) The pharmaceutical composition of claim 23, wherein the phospholipids are in a liquid crystalline phase at 37^0C.

39. (new) The pharmaceutical composition of claim 23, wherein the liposomes are obtainable by extruding phospholipid which is in a liquid crystalline phase at 37^{0}C through polycarbonate filters having a pore diameter of 0.1 micron.

40. (new) A pharmaceutical composition for the treatment of atherosclerosis, hyperlipidemia, or hypoalphalipoproteinemia, comprising a therapeutically effective amount of unilamellar liposomes consisting essentially of phospholipids having an average diameter of about 125 ± 30 nm obtainable by extruding phospholipids through filters.

41. (new) The pharmaceutical composition of claim 40 further comprising a pharmaceutically acceptable carrier.

42. (new) The pharmaceutical composition of claim 41 wherein the pharmaceutically acceptable carrier is selected from the group consisting of sterilized water, sterilized buffered water, sterilized saline solution, and a sterilized aqueous solution containing a compound selected from the group consisting of glycine, glycoproteins, albumin, lipoprotein, globulin, pH adjusting agents, buffering agents, tonicity adjusting agents, sodium acetate, sodium lactate, potassium chloride, calcium chloride, sodium chloride, and mixtures thereof.

43. (new) The pharmaceutical composition of claim 41 wherein the composition is lyophilized.

44. (new) The pharmaceutical composition of claim 41 wherein the concentration of liposomes in the carrier is about 200 mg/ml.

45. (new) The pharmaceutical composition of claim 41 wherein the concentration of liposomes in the carrier is about 100 mg/ml.

46. (new) The pharmaceutical composition of claim 41 wherein the concentration of liposomes in the carrier is in the range of 20-200 mg/ml.

47. (new) The pharmaceutical composition of claim 41 wherein the concentration of liposomes in the carrier is in the range of 50-150 mg/ml.

48. (new) The pharmaceutical composition of claim 40 wherein the liposomes are bound to apoproteins, lecithin-cholesterol acyltransferase, albumin or mixtures thereof.

49. (new) The pharmaceutical composition of claim 40, wherein the phospholipid is selected from the group consisting of egg phosphatidylcholine, egg phosphatidylglycerol, distearoylphosphatidylcholine, distearoylphosphatidylglycerol, phosphatidylcholine, phosphatidylglycerol, lecithin, β,γ-dipalmitoyl-α-lecithin, sphingomyelin, phosphatidylserine, phosphatidic acid, N-(2,3-di (9-(Z)-octadecenyloxy))-prop-1-yl-N,N,N-trimethylammonium chloride, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylinositol, cephalin, cardiolipin, cerebrosides, dicetylphosphate, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylglycerol, dioleoylphosphatidylglycerol, palmitoyl-oleoyl-phosphatidylcholine, di-stearoyl-phosphatidylcholine, stearoyl-palmitoyl-phosphatidylcholine, di-palmitoyl-phosphatidylethanolamine, di-stearoyl-phosphatidylethanolamine, di-myrstoyl-phosphatidylserine, di-oleyl-phosphatidylcholine, and mixtures thereof.

A1

50. (new) The pharmaceutical composition of claim 40, wherein the phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, and mixtures thereof.

51. (new) The pharmaceutical composition of claim 40, wherein the liposomes are obtainable by extruding phospholipid through filters having a pore diameter of 0.1 micron.

52. (new) The pharmaceutical composition of claim 40, wherein the liposomes are obtainable by extruding phospholipid through polycarbonate filters.